A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
about
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensA series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicidesA narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomesThree Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation CohortAdherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in BotswanaACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor lovirideMight ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?Use of observational data in evaluating treatments: antiretroviral therapy and HIV.The tolerability of efavirenz after nevirapine-related adverse events.Sex differences in nevirapine rash.Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in EthiopiaA sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboonsOverview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM developmentMortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in ChinaHIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report.Adherence to Antiretroviral Therapy Among Children Living with HIV in South India.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Palliative care for HIV disease in the era of highly active antiretroviral therapy.Management of the adverse effects of antiretroviral therapy and medication adherence.HIV protease inhibitor-related lipodystrophy syndrome.ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyTherapeutic interventions in HIV infection - a critical view.The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia.Comparison of NNRTIs in antiretroviral-naïve patients.Factors affecting adherence and convenience in antiretroviral therapy.Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months
P2860
Q24514773-681B4A6F-5EA2-4A4D-9EBD-FDD035A05242Q24534391-E5B8EE4A-5602-468E-B1F8-21D686347EABQ24563844-686B458E-4FDB-4BFE-B71F-2AC80807FE7FQ26796419-293E4854-C952-4639-AB4E-07362A2AA8BDQ27487454-3F6726A4-AA92-4802-A5A0-2D4AB463468FQ28221847-5E722DF5-2BD6-4572-8023-6DC7434788C0Q28362780-BD6A33BF-1B2C-4551-B5A7-84EC48C0025FQ28369293-4C43E0B5-4012-4255-88CE-E7E0A9A7D13DQ28555028-37A5302E-8C7C-43D6-BDA5-441E10069834Q30969932-88E84208-F708-4EAA-8E97-E43045108CE6Q31444144-508BCF92-41B1-4798-A837-E62E750106AFQ31704898-FFD0CB85-0467-4378-A6C6-E8F326A389EAQ33390518-B0A39759-FD3B-4F98-A3E5-84F46CC0FC4DQ33514519-6095EB5C-317F-4C80-A587-58A761F84058Q33564397-5B6B0775-C739-40BF-9C4B-C37B69594126Q33574798-FDEE2311-8EA4-4485-8FD5-0FFEF5D31071Q33586369-5583C134-4377-4FA1-BD9F-ED883FF16C2BQ33604216-7F70EEB0-9AA6-4091-83EA-0B9D2C7AEE9CQ33688291-3DDF24AE-E437-4CC0-8EB4-0D16F7C13E3FQ33724247-20AE782B-E51B-4A26-BCB1-1FD99DA43E8BQ33802477-C43D6144-D365-43A0-B1C2-EC239B4C26E6Q33803069-E47CB49F-348B-4D51-9F56-D412903C269EQ33803772-D42F1A90-C296-40E5-8746-E80E7D0DD64BQ33850152-C2FCF291-BFEA-41C7-89E5-A7D631630439Q33851627-4A9B8519-33EB-4C6B-B10B-DF2DAE83B5D9Q33873983-1B03EC2B-0A33-4DAA-8309-94ABB8C97DD8Q33944367-CEFDBD0B-0B51-4C29-9100-35D5820D7EE8Q33946887-9DEAA3CB-1F18-4774-84ED-B8DCD47E7EEBQ33946902-CF6398B9-2CD3-48CF-88DD-BDC2990A465BQ33976896-626D6710-3B1D-45AC-863C-8F91BD770F4CQ33980528-D96D846A-B1B4-4BBF-BA7C-125451B0BF55Q34018007-4FF88B02-10D3-41A5-B817-145717F4D30FQ34120588-486C9ADB-5A97-446C-9399-83E2945B12A9Q34283336-595B86BB-2769-491A-A14F-77FE072C201BQ34335232-3698B1C8-A0BC-48E3-8DD9-00C3EB19893DQ34394202-57BC7355-1890-451B-8F50-FCA11742BBD6Q34394220-4A556B82-D1B3-4A12-8B30-62F87AC5AC3AQ34394225-169DADDF-3DEC-4249-A96E-4ECFF485643FQ34462351-522229F1-5950-4203-A5BA-897B1460320BQ34465982-75D97024-B9AB-4B22-9FA4-21F0BBE72FEB
P2860
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A randomized, double-blind tri ...... s, Canada and Australia Study.
@ast
A randomized, double-blind tri ...... s, Canada and Australia Study.
@en
A randomized, double-blind tri ...... s, Canada and Australia Study.
@nl
type
label
A randomized, double-blind tri ...... s, Canada and Australia Study.
@ast
A randomized, double-blind tri ...... s, Canada and Australia Study.
@en
A randomized, double-blind tri ...... s, Canada and Australia Study.
@nl
prefLabel
A randomized, double-blind tri ...... s, Canada and Australia Study.
@ast
A randomized, double-blind tri ...... s, Canada and Australia Study.
@en
A randomized, double-blind tri ...... s, Canada and Australia Study.
@nl
P2093
P921
P356
P1476
A randomized, double-blind tri ...... s, Canada and Australia Study.
@en
P2093
J S Montaner
M A Wainberg
P304
P356
10.1001/JAMA.279.12.930
P407
P577
1998-03-01T00:00:00Z